Crossmark

Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022

Crossref DOI link: https://doi.org/10.1007/s10147-024-02491-6

Published Online: 2024-03-22

Published Print: 2024-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Uchino, Keita

Tamura, Shingo

Kimura, Shoji

Shigeta, Keisuke

Kimura, Takahiro

Ozaki, Yukinori

Nishio, Hiroshi

Tsuchihashi, Kenji

Ichihara, Eiki

Endo, Makoto

Yano, Shingo

Maruyama, Dai

Yoshinami, Tetsuhiro

Susumu, Nobuyuki

Takekuma, Munetaka

Motohashi, Takashi

Ito, Mamoru

Baba, Eishi

Ochi, Nobuaki

Kubo, Toshio

Kamiyama, Yutaro

Nakao, Shinji

Tamura, Shinobu

Nishimoto, Hitomi

Kato, Yasuhisa

Sato, Atsushi

Takano, Toshimi

Miura, Yuji https://orcid.org/0000-0002-7091-628X
License Information

Text and Data Mining valid from 2024-03-22

Version of Record valid from 2024-03-22
More Information

Article History

Received: 19 January 2024

Accepted: 12 February 2024

First Online: 22 March 2024

Declarations

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below